← Back to 3-MMC

3-MMC Stats & Data

Stimulant Empathogen Research-chemical

3m Meow Mcat 3-meph Metaphedrone 3mmc 3-methylmethcathinone 3methylmethcathinone

NPS DataHub

MW213.71

FormulaC11H16ClNO

CAS1246816-62-5

IUPAC2-(Methylamino)-1-(3-methylphenyl)propan-1-one

SMILES[Cl-].CNC(C)C(=O)c1cccc(C)c1.[H+]

Phenethylamines; Cathinones; 2020/1. Von 2-Phenethylamin abgeleitete Verbindungen; 2021/1. Von 2-Phenethylamin abgeleitete Verbindungen; 2022/1. Von 2-Phenethylamin abgeleitete Verbindungen

Chemical Class Cathinone

Psychoactive Class Stimulant / Entactogen

Interaction Warnings

⚠ mdma

The neurotoxic effects of MDMA may be increased when combined with other stimulants.

⚠ cocaine

This combination may increase strain on the heart.

Receptor Profile

Receptor Actions

Inhibitors

Serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI)

Other

Serotonin-norepinephrine-dopamine releasing agent (SNDRA)

History & Culture

2012–present

3-MMC was first encountered in Sweden in 2012, emerging on the online research chemical market shortly after the banning of mephedrone in numerous countries. It was created as a designer drug specifically chosen to mimic and replace the functional and structural features of its recently-controlled predecessor. The compound was sold as a research chemical, typically in powdered form, and quickly became a prominent example of contemporary designer drug development in response to prohibition. There is no known or reported medical use of 3-MMC; since its emergence it has been used primarily for recreational purposes.

2016–2023

In 2016, the United Nations Office on Drugs and Crime conducted a critical review of 3-MMC but ultimately decided not to recommend international control. However, following a subsequent period of increased abuse beginning around 2019, this decision was revisited. The earlier assessment was overturned and 3-MMC was placed into Schedule II of the United Nations Convention on Psychotropic Substances 1971 in March 2023, prompting many member nations to implement or strengthen domestic controls.

2023–present

Despite its prohibition as a recreational substance, 3-MMC has attracted interest as a potential pharmaceutical compound. The biotechnology company Clearmind Medicine has been developing 3-MMC for the potential treatment of dyskinesias, with the compound in preclinical research as of August 2023. American biotech company MindMed has filed patents to use 3-MMC for conditions including social anxiety disorder, post-traumatic stress disorder, and as an adjunct in couples therapy. Additionally, the Dutch company Period Pill has been conducting clinical trials investigating 3-MMC for the treatment of menstrual symptoms, with a successful trial completed at the University of Maastricht. The company has sought patent coverage in multiple jurisdictions. The first in-human clinical safety study of 3-MMC was published in December 2024, marking a significant milestone in the compound's transition from unregulated research chemical to potential therapeutic agent.

Effect Profile

Curated + 26 Reports

Empathogen 9.6

Strong empathy, euphoria, and sensory enhancement with moderate stimulation

Empathy / Social Openness×3

107.5

Euphoria / Mood Elevation×2

1010

Stimulation×1

79.6

Sensory Enhancement×1

104.4

Catalog BlueLight

Stimulant 5.1

Strong euphoria and anxiety/jitters with mild stimulation, low focus

Stimulation / Energy×3

Euphoria / Mood Lift×2

Focus / Productivity×2

Anxiety / Jitters×1

Based on reports from:

Erowid Experience Reports PsychonautWiki 3-MMC The Drug Users Bible 3-MMC

Tolerance & Pharmacokinetics

drugs.wiki

Tolerance Decay

Full tolerance 1h Half tolerance 4d Baseline ~5d

Experience Report Analysis

Erowid BlueLight

17 Reports

2012–2023 Date Range

15 With Age Data

14 Effects Detected

Demographics

Gender Distribution

Age Distribution

Reports Over Time

Effect Analysis

Erowid + Bluelight

Effects aggregated from 26 experience reports (17 Erowid + 9 Bluelight)

26 Reports

48 Effects Detected

16 Positive

20 Adverse

12 Neutral

Effect Sentiment Distribution

Confidence Distribution

Positive Effects 16

Euphoria 73.1% 84%

Stimulation 57.7% 85%

Empathy 50.0% 83%

Sociability Enhancement 44.4% 81%

Body High 44.4% 85%

Contentment 33.3% 92%

Thought Acceleration 33.3% 75%

Focus Enhancement 30.8% 78%

Tactile Enhancement 29.4% 70%

Music Enhancement 26.9% 85%

Tingling 22.2% 88%

Joy 22.2% 85%

Libido Enhancement 22.2% 85%

Introspection 17.6% 70%

Orgasm Enhancement 11.1% 80%

Enhanced Colors 11.1% 75%

Adverse Effects 20

Insomnia 33.3% 85%

Confusion 29.4% 70%

Jaw Clenching 26.9% 78%

Muscle Tension 23.5% 70%

Anxiety 23.1% 85%

Irritability 22.2% 82%

Emotional Blunting 11.1% 65%

Nausea 11.1% 70%

Dry Mouth 11.1% 75%

Metallic Taste 11.1% 80%

Headache 11.1% 70%

Diarrhea 11.1% 75%

Body Load 11.1% 80%

Distractibility 11.1% 80%

Muscle Spasm 11.1% 90%

Dizziness 11.1% 85%

Hot Flashes 11.1% 90%

Cold Flashes 11.1% 85%

Restlessness 11.1% 85%

Sadness 11.1% 80%

Real-World Dose Distribution

62K Doses

From 28 individual dose entries

Oral (n=15)

Median: 100.0mg 25th: 72.5mg 75th: 155.0mg 90th: 176.0mg

mg/kg median: 1.653 mg/kg 75th: 2.112

Form / Preparation

Most common forms and preparations reported

Redose Patterns

Redosing behavior across 13 reports

53.8% Redosed

1.9 Avg Doses

60m Median Interval

Read full reports on Erowid →

Legal Status

UN Convention on Psychotropic Substances 1971 (Schedule II, placed March 2023)

Country	Status	Notes
Austria	Illegal (NPSG)	Prohibited under the Neue-Psychoaktive-Substanzen-Gesetz (New Psychoactive Substances Act). Possession, production, and sale are illegal.
Brazil	Illegal	Listed on Portaria SVS/MS nº 344. Possession, production, and sale are prohibited under this regulation.
China	Controlled	Banned since October 2015 along with numerous other synthetic compounds. This ban significantly impacted global availability as Chinese chemical companies were primary manufacturers.
Czech Republic	Illegal	Banned substance under national drug control legislation.
Germany	Anlage I BtMG	Controlled under Anlage I of the Betäubungsmittelgesetz (Narcotics Act, Schedule I) since December 13, 2014. Manufacturing, possession, import, export, purchase, sale, procurement, and dispensing without license are prohibited.
India	Narcotic	Designated as a narcotic substance on February 8, 2024, making possession, production, and distribution illegal.
Netherlands	List I (Opiumwet)	Initially classified as a List II (soft drug) substance effective October 28, 2021. Subsequently reclassified to List I (hard drug) in April 2024, carrying more severe penalties for possession and distribution.
Poland	II-P Category Drug	Classified as a II-P category controlled substance since April 25, 2024, making possession, production, and distribution illegal.
Sweden	Narcotic	Classified as a narcotic substance under Swedish drug control legislation.
Switzerland	Controlled (Verzeichnis E)	Regulated as a defined derivative of cathinone under Verzeichnis E point 1. Use is permitted for legitimate scientific or industrial purposes only.
Turkey	Illegal	Classified as a controlled drug. Possession, production, supply, and importation are prohibited.
United Kingdom	Class B	Controlled as a Class B substance under the Misuse of Drugs Act 1971 through the cathinone catch-all clause, which covers structurally related compounds.
United States	Schedule I	Illegal as a positional isomer of the controlled substance mephedrone. Explicitly designated as a controlled substance on December 13, 2023, and categorized by the DEA as a Schedule I positional isomer.

References

Data Sources

Cited References

← Back to 3-MMC